Medivir Ab

Janssen R&d Ireland

Infex Therapeutics Limited

Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd. Co

Hans Kristian Wallberg

Bertil Samuelsson

Christer Sahlberg

Bengt Bertil Samuelsson

Kenneth Simmen

Åsa Annica Kristina Rosenquist

Genaidy Kalyanov

Lotta Naeslund

Kevin Parkes

Pierre Jean-Marie Bernard Raboisson

Piaoyang Sun

Lili Hu

Herman Augustinus De Kock

Karl Magnus Nilsson

Tony Johnson

Per-Ola Mikael Johansson

Ingemar Sven-Anders Kvarnstrom

Stefan Lindstrom

Asa Rosenquist

Fredrik Thorstensson

Guo-Qiang Lin

Ian Cooper

David Orr

Andrew Wilkinson

Jonathan Finlayson

Adam Bunt

Pia Appelqvist

Fredrik Wångsell

Xin-Sheng Lei

Ming-Hua Xu

Abdellah Tahri

Sandrine Marie Helene Vendeville

Bart Rudolf Romanie Kesteleyn

Dominique Louis Nestor Ghislain Surleraux

Pia Kahnberg

Xiao-Xiong Zhou

Lourdes Salvador Oden

Horst Wahling

Wim Van De Vreken

Christian Sund

Dmitry Antonov

Genadiy Kalayanov

Wim Bert Griet Schepens

Anna Karin Gertrud Linnea Belfrage

Björn Olof Classon

Johannes Wilhelmus J Thuring

Rolf Nor&eacute;en

Carl Erik Daniel Jönsson

Lourdes Salvador Odén

Nils Gunnar Johansson

Stefan Lindström

Mats Stefan Lindström

Ismet Dorange

Susana Ayesa Alvarez

Jörg Kurt Wegner

Horst Jürgen Wähling

Karin Charlotta Lindquist

Bjorn Olaf Classon

Mahalingam Kannan

Karl Magnus Milsson

Herman Agustinus De Kock

Lourdes Salvador

Susana Ayesa Alverez

Lourdes Salvador Od&eacute;n

Stefan Lindstr&ouml;m

Yvan Simonnet

Jenny Ekegren

Anders Hallberg

Sven Crister Sahlberg

Kenneth Alan Simmen

Joerg Kurt Wegner

Horst Jürgen WÄHLING

ÅSa Annica Kristina Rosenquist

Pia Cecilia Kahnberg

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

Antibacterial compounds

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-&#x3b2;-lactamase inhibitors. 

Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. 

HCV NS-3 serine protease inhibitors

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein the dashed line, X, R, R, R, R, R, R, and Rhave defined meanings; the preparation thereof; compositions containing compounds of formula (I), including bioavailable combinations with ritonavir; and the pharmaceutical uses thereof.

Macrocyclic inhibitors of hepatitis C virus

HIV inhibitors of formula (I) wherein Ris halo, Calkoxy, trifluoromethoxy; Ris a group of formula (A); Ris a group of formula (B); Ris a group of formula (C); n is 0 or 1; A is CH or N; Rand Rare hydrogen, Callyl, halo; Rand Rare Callyl or Calkoxy-Calkyl; Ris Callyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; Ris hydrogen, Calkyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.

5-amino-4-hydroxypentoyl amides

The invention provides compounds of the formula (I)  wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).

(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD). 

(2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.

Compounds of the formula I: wherein The compounds have utility as HIV-1 protease inhibitors.

HIV protease inhibitors

Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. 

Compounds of the formula I: and N-oxides, salts, and stereoisomers thereofwherein

Macrocylic inhibitors of hepatitis C virus

This invention relates to non-nucleoside reverse transcriptase inhibitors active against HIV-1 and having an improved resistance and pharmacokinetic profile. The invention further relates to novel intermediates in the synthesis of such compounds and the use of the compounds in antiviral methods and compositions.

Non-nucleoside reverse transcriptase inhibitors

Intermediate compounds of non-nucleoside reverse transcriptase inhibitors

Growing community of inventors

Hagersten, Sweden

Hans Kristian Wallberg